Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-11-26 00:00:00 ET · period of report 2024-11-22 · accession 0001787306-24-000161 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-26 | 2024-11-22 | ARQT | Burnett Patrick | See Remarks | M - OptEx | $0.00 | +16.0K | 144.7K | +12% | $0 |
| D | 2024-11-26 | 2024-11-22 | ARQT | Burnett Patrick | See Remarks | S - Sale+OE | $10.14 | -16.0K | 128.7K | -11% | -$162.5K |
| D | 2024-11-26 | 2024-11-22 | ARQT | Burnett Patrick | See Remarks | M - OptEx | $0.00 | -16.0K | 218.5K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-22 | M | A | 16,023 | $0.00 | 144,692 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-22 | S | D | 16,023 | $10.14 | 128,669 | D | — | — | (F1) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $10.205 to $10.14, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Derivative | Stock Option (right to buy) | 2024-11-22 | M | D | 16,023 | $0.00 | 218,500 | D | $3.64 · — to 2034-01-12 | 16,023 Common Stock | (F2) On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. |